Literature DB >> 31686528

Medication for addiction treatment and acute care utilization in HIV-positive adults with substance use disorders.

K Thakarar1,2, A Y Walley3,4, T C Heeren5, M R Winter5, A S Ventura3, M Sullivan3, M Drainoni4,5,6, R Saitz3,4,5,7.   

Abstract

Medication for addiction treatment (MAT) could reduce acute care utilization in HIV-positive individuals with substance use disorders. The study objective was to determine if HIV-positive people with substance use disorders treated with MAT report less acute care utilization than those not receiving MAT. We assessed the association between MAT and acute care utilization among HIV-positive individuals with alcohol or opioid use disorder. Acute care utilization 6 months later was defined as any past 3-month self-reported (1) emergency department (ED) visit and (2) hospitalization. Of 153 participants, 88% had alcohol use disorder, 41% had opioid use disorder, and 48 (31%) were treated with MAT. Fifty-five (36%) participants had an ED visit and 38 (25%) participants had a hospitalization. MAT was not associated with an ED visit (AOR 1.12, 95% CI 0.46-2.75) or hospitalization (AOR 1.09, 95% CI 0.39-3.04). MAT was not associated with acute care utilization. These results highlight the need to increase MAT prescribing in HIV-positive individuals with substance use disorders, and to address the many factors that influence acute care utilization.

Entities:  

Keywords:  HIV infections; health services; social determinants of health; substance-related disorders

Year:  2019        PMID: 31686528      PMCID: PMC7198361          DOI: 10.1080/09540121.2019.1683805

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  9 in total

1.  Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population.

Authors:  Bruce Arroll; Felicity Goodyear-Smith; Susan Crengle; Jane Gunn; Ngaire Kerse; Tana Fishman; Karen Falloon; Simon Hatcher
Journal:  Ann Fam Med       Date:  2010 Jul-Aug       Impact factor: 5.166

Review 2.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

3.  Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?

Authors:  S J Rolnick; E D Parker; J D Nordin; B D Hedblom; F Wei; T Kerby; J M Jackson; A L Crain; G Euler
Journal:  Vaccine       Date:  2013-06-24       Impact factor: 3.641

4.  Medications For Addiction Treatment: Changing Language to Improve Care.

Authors:  Sarah E Wakeman
Journal:  J Addict Med       Date:  2017 Jan/Feb       Impact factor: 3.702

5.  Reliability of alcohol abusers' self-reports of drinking behavior.

Authors:  L C Sobell; S A Maisto; M B Sobell; A M Cooper
Journal:  Behav Res Ther       Date:  1979

6.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

Review 7.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

8.  Integrated opioid use disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies.

Authors:  Marcelo F Batkis; Glenn J Treisman; Andrew F Angelino
Journal:  AIDS Patient Care STDS       Date:  2010-01       Impact factor: 5.078

9.  Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS).

Authors:  Laura Campbell-Sills; Sonya B Norman; Michelle G Craske; Greer Sullivan; Ariel J Lang; Denise A Chavira; Alexander Bystritsky; Cathy Sherbourne; Peter Roy-Byrne; Murray B Stein
Journal:  J Affect Disord       Date:  2008-05-16       Impact factor: 4.839

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.